To evaluate the impact of nocturia on patients' quality of life and healthcare resource utilisation (HRU) compared with overactive bladder (OAB) and benign prostatic hyperplasia (BPH).
Data were drawn from a multinational (France, Germany, Spain, UK and US) survey of physician and patient-reported outcomes.